Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 251 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is C  [Clear All Filters]
2020
Gordhandas S, Kahn RM, Gamble C, Talukdar N, Maddy B, Nelson BBaltich, Askin G, Christos PJ, Holcomb K, Caputo TA et al..  2020.  Clinicopathologic features of endometrial cancer with mismatch repair deficiency.. Ecancermedicalscience. 14:1061.
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, J Cairncross G, Wick W, Weller M et al..  2020.  CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.. Neuro Oncol.
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, J Cairncross G, Wick W, Weller M et al..  2020.  CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.. Neuro Oncol.
Ahmad FS, Ricket IM, Hammill BG, Eskenazi L, Robertson HR, Curtis LH, Dobi CD, Girotra S, Haynes K, Kizer JR et al..  2020.  Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.. Circ Cardiovasc Qual Outcomes. 13(6):e006292.
Grinspan ZM, Mytinger JR, Baumer FM, Ciliberto MA, Cohen BH, Dlugos DJ, Harini C, Hussain SA, Joshi SM, Keator CG et al..  2020.  Crisis Standard of Care: Management of Infantile Spasms during COVID-19.. Ann Neurol.
Grinspan ZM, Mytinger JR, Baumer FM, Ciliberto MA, Cohen BH, Dlugos DJ, Harini C, Hussain SA, Joshi SM, Keator CG et al..  2020.  Crisis Standard of Care: Management of Infantile Spasms during COVID-19.. Ann Neurol.
Grinspan ZM, Mytinger JR, Baumer FM, Ciliberto MA, Cohen BH, Dlugos DJ, Harini C, Hussain SA, Joshi SM, Keator CG et al..  2020.  Crisis Standard of Care: Management of Infantile Spasms during COVID-19.. Ann Neurol.
Ono JG, Kim BI, Zhao Y, Christos PJ, Tesfaigzi Y, Worgall TS, Worgall S.  2020.  Decreased sphingolipid synthesis in children with 17q21 asthma-risk genotypes.. J Clin Invest. 130(2):921-926.
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC et al..  2020.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.. Oncotarget. 11(22):2074-2082.
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC et al..  2020.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.. Oncotarget. 11(22):2074-2082.
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC et al..  2020.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.. Oncotarget. 11(22):2074-2082.
Ezeomah C, Cunningham KA, Stutz SJ, Fox RG, Bukreyeva N, Dineley KT, Paessler S, Cisneros IE.  2020.  Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats.. Brain Behav Immun.
Ezeomah C, Cunningham KA, Stutz SJ, Fox RG, Bukreyeva N, Dineley KT, Paessler S, Cisneros IE.  2020.  Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats.. Brain Behav Immun.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Mao J, Chughtai B, Ibrahim S, Sedrakyan A.  2020.  Food and Drug Administration Safety Communication on the Use of Transvaginal Mesh in Pelvic Organ Prolapse Repair Surgery: The Impact of Social Determinants of Health.. Female Pelvic Med Reconstr Surg.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.